Kornimate/medical-research-clean huggingface dataset:
pirlong-pd safety and efficacy of piribedil in parkinson's disease during long term therapy

Conditions: Parkinson's Disease

Summary: non-ergot dopamine agonists are meanwhile the drugs of first-choice in the treatment of parkinson's disease. the receptor profile of the non-ergot dopamine-agonist piribedil is unique. in addition to agonistic effects on dopaminergic d2- and d3-receptors piribedil has adrenergic alpha-2a- and alpha-2c-receptors antagonisic properties. there is evidence from the literature that the antagonistic properties of piribedil are correlated with an improvement of cognitive function and vigilance parameters in parkinson's disease. the aim of the present non-interventional study is to investigate the safety and efficacy of piribedil during long-term therapy of patients with m. parkinson under consideration of cognitive functions and quality of life.


Eligibility criteria:
inclusion criteria: * newly diagnosed or advanced idiopathic parkinson's disease * male and female patients over 18 years of age * indication for treatment with piribedil according to summary of product characteristics (smpc) exclusion criteria: * in line with piribedil smpc * in particular hypersensitivity to piribedil or to any of the excipients and pregnancy and lactation as stated in the smpc

Keywords: open non-intervention observational
effects of exercise and back counselling for nurses

Conditions: Low Back Pain

Summary: low back pain (lbp) is most common occupational health problem among nurses. therefore, how to prevent and reduce low back pain have been the important issue for nurses. a quasi-experimental design is used in this study to compare the effectiveness of 12-week exercise and counselling program to reduce low back pain in nursing personnel compared with counselling alone.

a quasi-experimental design is used in this study. purposive sampling is used to recruit participants from medical center in central taiwan. participants will be randomly assigned to two groups: (1) exercise and back counselling, and (2) back counselling only. the results of this study will provide a guideline for nurses to prevent and to improve low back pain.

Eligibility criteria:
inclusion criteria: 1. has worked at current job for at least 12 months; 2. intensity of low back pain on visual analogue scale (scale 0-10) at least two during the past 3 months. exclusion criteria: 1. serious former back injury (fracture, surgery, disc protrusion); 2. pregnant; 3. other serious disease or symptoms that limit participation exercise defined by a physician.
treatment of disruptive behaviors in fragile x syndrome

Conditions: Fragile X Syndrome; Disruptive Behavior

Summary: disruptive behaviors such as self-injury, aggression, and property destruction pose significant health-related issues to children diagnosed with fragile x syndrome (fxs), impacting the child's quality of life and causing significant distress to families. access to appropriate treatment for families is severely limited by factors such as cost of care, shortages of qualified treatment providers, and geographic spread of children with fxs across the country. to address these potential issues, the effectiveness of administering a standardized function-based behavioral treatment for problem behaviors in fxs will be evaluated using telemedicine. the proposed study intervention therefore offers a tremendous step forward in clinical research both in the field of fxs and in the field of developmental disabilities more broadly, and thus will have a significant impact on public health.


Eligibility criteria:
inclusion criteria: 1. child has a confirmed diagnosis of fxs (\>200 cgg repeats on the fmr1 gene with evidence of aberrant methylation) 2. child is male, between the ages of 3-10 years old 3. child is reported to show self-injury, property destruction and/or aggression on at least a daily basis 4. the caregiver agrees to keep any therapies that the child receives (i.e., medications or other treatments) as stable as possible throughout involvement in the study 5. the family has a high-speed internet connection at home or lives in an area with 4g network coverage 6. availability for one-hour daily telemedicine treatment sessions 7. availability for in-home assessment totaling 8 hours across two consecutive days exclusion criteria: 1. the child or caregiver has significant sensory impairments (e.g., blindness or deafness) 2. non-english speaking 3. the child receives applied behavior analysis services in excess of five hours per week 4. the child has a significant neurological condition (e.g., frequent seizures, brain injury, tourette's syndrome) that would preclude participation 5. the child or caregiver has significant mobility issues 6. the child is currently participating in another research study that would preclude participation in the study
effect of endometrial scratching on assisted reproduction outcomes: a randomized controlled trial

Conditions: Subfertility

Summary: to examine whether endometrial scratching (or injury) using a pipelle endometrial sampler, performed on the first seven days of the menstrual cycle, is able to improve pregnancy rates in women who will be submitted to a fresh embryo transfer.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * first four days of the menstrual cycle, just before starting controlled ovarian stimulation for planned ivf and fresh embryo transfer. * not have performed endometrial scratching in the last 90 days. exclusion criteria: * none

Keywords: ivf icsi embryo transfer assisted reproduction endometrial injury endometrial scratching
a low dose dexmedetomidine in sedation colonoscopy

Conditions: Colonoscopy

Summary: 104 patients who undergo painless colonoscopy from january 20,2024 to february 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. in the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. in the propofol group, propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 during the whole process.

104 patients who undergo painless colonoscopy from january 20,2024 to february 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. in the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. in the propofol group, propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1.for all patients, if ramsay sedation scale score reach 3, colonoscope will be inserted. during the whole process, maintenance ramsay score of 3 to 4. propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy. the primary outcome is the occurrence of hypotension. key secondary outcomes are time-weighted average (twa), area under the threshold (aut) and cumulative duration of hypotension, as well as the maximum reduction in bp. other secondary outcomes include(1) the incidence of bradycardia, hypoxemia or body movement；(2) discharge time (from the end of colonoscopy to discharge); (3) patients and endoscopists' satisfaction score (using an 11-point likert scale, with 0 indicating "very dissatisfied" and 10 indicating "very satisfied"); (4) the incidence of dizziness, fatigue, or nausea and vomiting

Eligibility criteria:
inclusion criteria: 1. patients aged above 18 years 2. american society of anesthesiologists (asa) physical status of 1-2 3. patients scheduled for sedation colonoscopy exclusion criteria: 1. emergency patients 2. body weight \ 100 kg 3. allergy to dexmedetomidine, propofol in this trail, a previous adverse reaction to dexmedetomidine or propofol 4. pregnancy or lactation 5. drug abusers 6. participation in other clinical studies within the previous 3 months 7. renal impairment (glomerular filtration rate \ 1.5)
4-pba: will it increase the level of alpha 1-antitrypsin(aat) in persons with aat deficiency?

Conditions: Alpha 1-Antitrypsin Deficiency

Summary: the purpose of this study is to find out whether 4-pba will increase the level of aat in persons with aat deficiency whether or not they have liver disease.

the purpose of this study is to determine whether 4-pba will significantly increase serum z aat levels in aat-deficient individuals with and without evidence of hepatocellular injury and to assess its effects on liver injury.

Eligibility criteria:
inclusion criteria: * age 18-65 * serum a1-pi levels \<11um an appropriate genetic phenotype/genotype * 5 of 10 subjects must have documented laboratory evidence of liver disease * willingness to withhold prolastin therapy for 6 weeks prior to screening and throughout the 4-pba dosing period (up to 3 months) exclusion criteria: * any cause of liver disease other than alpha-1 antitrypsin deficiency * evidence of advanced liver disease * hiv positive * use of systemic steroids, ursodeoxycholic acid (actigall, urso), or herbs in the prior 6 months

Keywords: pulmonary disease liver disease
a motor learning intervention to target walking performance in ambulant children with cerebral palsy

Conditions: Cerebral Palsy; Walking, Difficulty; Spastic Diplegia; Hemiplegic Cerebral Palsy

Summary: the goal of this clinical trial is to learn if a new therapy approach to improve walking ability in children with cerebral palsy is acceptable to the children and the families in a community setting. the main questions we look to answer are: 1. do the children/teens tolerate the therapy and feel that it is helpful? 2. do the parents/ families feel the therapy helps and is easy to commit to? 3. do the children/teens complete all their therapy sessions and assessments as planned? the participants will trial the therapy for 30 hours over 6 weeks and will perform assessments before and after to see if they meet their goals. they will also be interviewed to see how they felt about the therapy when they finish.

the therapy being trialed in this study uses motor learning theory to try and improve or change walking patterns to improve the child/teen's walking goal. therapy will target their own walking goal and they can choose the format of their therapy as long as they complete 30 hours of which 24 hours must be in the clinic within a 6 week period.

Eligibility criteria:
inclusion criteria: * primary diagnosis of cerebral palsy (gmfcs levels i-iii) * has a specific walking related goal * has capacity to follow instruction * has a primary caregiver who can support a home program exclusion criteria: * has had surgery within 6 months of intervention start date * has had botox/ baclofen within 3 months of intervention start date * has a dual diagnosis that impacts ability to follow instruction * has a significant cognitive impairment

Keywords: motor learning theory neuroplasticity neurological rehabilitation
clinical observation and mri influence of acupuncture on knee osteoarthritis

Conditions: Knee Arthritis Osteoarthritis

Summary: to observe the therapeutic effect of acupuncture on osteoarthritis(oa) and its efficacy on cartilage restoration,acupuncture and physiotherapy treatment were respectively given to two random groups. western ontario and mcmaster universities osteoarthritis index (womac) was used to evaluate the motor function of knee joints, followed by magnetic resonance imaging (mri) scanning to measure t2 values in ten cartilage sub-regions in tibiofemoral joints.

to observe the therapeutic effect of acupuncture on osteoarthritis and its efficacy on cartilage restoration,one hundred knees of 50 patients with knee osteoarthritis were randomly divided into acupuncture group and physiotherapy group which were respectively received acupuncture and physiotherapy treatment for four weeks. western ontario and mcmaster universities osteoarthritis index (womac) was used to evaluate the motor function of knee joints, followed by magnetic resonance imaging (mri) scanning to measure t2 values in ten cartilage sub-regions in tibiofemoral joints.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as knee osteoarthritis according to the oa criteria proposed by american college of rheumatology in 1995. exclusion criteria: * acute knee injury * had ever accepted therapy as hormone or injection in articulation cavity * had ever accepted treatment as oral medicine, physiotherapy, acupuncture or massage during the passed three months * had planted cardiac pacemaker or any metal matter in body * other severe diseases such as heart, lung, liver, kidney or cerebrum failure, tumors, gastrointestinal hemorrhage and so on * pregnant or lactating woman * anyone unable to tolerate or cooperate with treatment.

Keywords: osteoarthritis mri cartilage acupuncture
epidemiology of coronary calcification in the elderly

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Arteriosclerosis; Coronary Disease; Hypertension

Summary: to investigate the prevalence and prognostic value of subclinical atherosclerosis in the pittsburgh shep cohort and a cohort of normal controls.

background: this is an ancillary study to the systolic hypertension in the elderly program (shep) design narrative: continued annual telephone follow-up of the remaining 178 pittsburgh shep participants and 168 controls will be conducted . a final clinic visit will include measures of coronary and aortic calcification using electron beam computed tomography (ct), pulse wave velocity as a measure of aortic stiffening and cognitive function testing. for the pittsburgh shep cohort, the antihypertensive treatment effect has been striking with event rates for the active and placebo groups continuing to diverge beyong the end of shep. successful demonstration of a treatment effect on coronary calcium scores would be the first randomized data showing an antihypertensive effect directly in the coronary arteries. risk factors for coronary calcification will be evaluated, producing data of a type not yet available in the literature for older adults and not being collected in any other ongoing studies of the elderly. the added measures of vascular stiffness will supplement the extensive data on subclinical atherosclerosis already available for this cohort. the extent to which these measures predict cardiovascular events will be evaluated. the study has been renewed through july 2006. since hypertension and aging are associated with cognitive impairment and vascular dementia, shep participants assigned to the placebo group are expected to have lower cognitive function compared to those assigned to active treatment. among both hypertensive and normotensive groups, lower cognitive function among those with evidence of subclinical atherosclerosis is expected. finally, members of the cohort who were originally normotensive at study entry are now developing systolic hypertension. these subjects will allow a prospective evaluation of risk factors for systolic hypertension. continued study of this cohort into their 80s will provide unique data on the risks and etiology of systolic hypertension, the efficacy of its treatment and the prognostic value of a number of measures of subclinical atherosclerosis. it is predicted that the results will be directly applicable to the largest growing segment of the u.s. population.

Eligibility criteria:
participating in the cardiovascular health study (chs) at the university of pittsburgh site. inclusion criteria: age 65 or older in 1989-90 able to give informed consent able to travel to study site no plans to move from the area within 3 years of chs enrollment exclusion criteria: inability to give informed consent at time of ebct scan unable to travel to study center lives in nursing home.
three-dimensional t1rho using spiral fast spin echo

Conditions: Liver Fibrosis

Summary: liver fibrosis is the main feature in early chronic liver diseases. if identified early, liver fibrosis is reversible. the current gold standard for diagnosing liver fibrosis is invasive liver biopsy. existing non-invasive methods still have significant limitations. t1rho imaging is a promising non-invasive technology evaluating liver fibrosis. it does not require exogenous contrast agent or extra hardware. however, it remains challenging to perform t1rho measurements of the liver. the rich blood signal in the liver introduces quantification errors of liver parenchyma. the existing black blood mri technologies are based on cartesian fse acquisitions, which are not optimal for liver imaging. the residual blood signal is often observed which confounds the measurement. current t1rho measurement of the liver is mostly performed in two-dimension. 3d coverage of liver is desirable. however, 3d t1rho imaging of liver suffers from long scan time due to increased spatial coverage, reduced scan time efficiency from motion compensation, and high specific absorption rate (sar). the investigators aim to overcome these challenges by developing 3d t1rho imaging technologies based on magnetization prepared spiral fse acquisition. compared to cartesian fse, spiral fse traverses k-space more efficiently per unit of time, and has reduced sar due to significantly decreased number of radiofrequency pulses in the echo trains. spiral acquisition has zero gradient moment at the kspace center, which substantially reduces its sensitivity to respiratory motion. the residual motion manifests as benign incoherent artifacts in the image domain rather than detrimental structured artifacts. differently to cartesian fse, spiral fse provides flexibility to design and optimize flow-sensitizing gradients throughout the echo trains to achieve superior suppression of blood signal. the investigators will evaluate the proposed pulse sequences in both healthy controls and patients with liver fibrosis. this project will provide new black blood imaging technologies and a 3d diagnostic tool for early detection of liver fibrosis. this will improve clinical outcomes for patients with chronic liver disease, and provide a springboard for further development of mri technology for other purposes.


Eligibility criteria:
inclusion criteria: * between age 18 and age 55 * patients with early liver fibrosis * informed written consent obtained exclusion criteria: * contraindications to mri such as the presence of metallic implants, claustrophobia and pregnancy

Keywords: 3d, t1rho, fast spin echo
cold magnesium sulfate solution for perineal swelling following vaginal delivery

Conditions: Vaginal Delivery; Perineal Swelling; Perineal Pain

Summary: the purpose of this study is to compare the impact of treatment with cooled magnesium sulfate and cold water-soaked pads on perineal pain and swelling following vaginal delivery. assessment of appropriateness for each patient to take part in the study will be performed approximately 2 hours following delivery. those patients who consent to participate in the trial will be allocated to treatment groups in a double-blinded, randomized manner. women in the study group will receive treatment with pads soaked in a cold aqueous solution of magnesium sulfate at 33% (w/v) concentration, while those in the control group will receive treatment with pads soaked in cold water. nurses will initiate treatment according to the group to which the patient was randomized. said pads will be given the patients routinely 5 times a day at regular times. a physician will assess the perineal swelling according to visual (photographed) scale in which severe, moderate, light and no swelling will be defined. measurement of swelling in centimeters (maximal length and breadth); photography, by a medical photographer or the examining doctor, of the perineal area with a centimeter ruler, before, during and after treatment (photography is dependent on patient approval and is not a precondition to participation in the trial.); and additional examination, on the above basis, will be performed regarding hemorrhoids in the event that a patient has complained of such. a nurse will assess the perineal pain and swelling on a scale ranging from 0 to 10 prior to the patient being given the pad and an hour following treatment. an additional assessment by the same method will be performed regarding hemorrhoid pain. any analgesia administered will also be recorded. likewise, for follow-up purposes a blood test for serum magnesium concentration will be taken before and after treatment. period of follow-up will be 48-72 hours from childbirth.


Eligibility criteria:
inclusion criteria: * parturients following normal vaginal birth or vacuum-assisted vaginal delivery * reporting of perineal pain equal to or greater than 3 on a 0-10 scale exclusion criteria: * parturients following cesarean section * lack of consent to take part in the study * parturients interested in early discharge (within 48 hours of childbirth) * girls under 18 years of age

Keywords: vaginal delivery perineal swelling perineal pain mgso4 magnesium sulfate cold water
effect of memantine on functional communication in patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with alzheimer's disease


Eligibility criteria:
inclusion criteria: * male and female outpatients, 50 years or older, native english speakers, meeting national institute of neurological and communicative disorders and stroke--alzheimer's disease and related disorders association (nincds-adrda) criteria for probable ad with a mini mental state examination (mmse) score of 10 to 19 at screening and baseline exclusion criteria: * current diagnostic and statistical manual of mental disorders--fourth edition (dsm-iv) axis i disorder other than ad * previous imaging results not consistent with the diagnosis of ad * modified hachinski ischemia score greater than 4 * evidence of other neurologic disorders * clinically significant systemic disease * a known or suspected history of alcohol or drug abuse in the past 5 years * taking excluded medication * previous treatment with commercial memantine

Keywords: memantine alzheimer's disease communication